Dual-chemokine-armed oncolytic Senecavirus A co-recruits cDC1 and CXCR3+ T cells to convert 'cold melanoma and drive durable regression

Background <p>Oncolytic virotherapy represents a promising anticancer strategy by combining direct tumor lysis with in situ immune activation. However, its efficacy remains limited in immune-cold tumors, which are characterized by poor T-cell infiltration and an immunosuppressive microenvironment. Although engineering oncolytic viruses to deliver chemokines has been explored to modulate immune recruitment, most existing approaches activate only a single immune axis.…